Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

Ru Han; Clément François; Mondher Toumi

doi:10.1101/2020.06.22.20135434

Data Availability

The data relating to the systematic review are all included in the article and/or its supplementary materials. The model used in the study can be made available to researchers upon request.

Comments

medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our Comment Policy before commenting. The content of a comment is not endorsed by medRxiv.

Community Reviews

medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors.

Community reviews for this article:

There are no community reviews for this paper.

Automated Evaluations

Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv.

Automated Evaluations:

There are no automated evaluations for this paper.

Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

Data Availability

Subject Area

Citation Manager Formats

Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

Data Availability

Subject Area

Follow this preprint